The Safety and Tolerability of Sub-retinal Transplantation of SCNT-hES-RPE Cells in Patients With Advanced Dry AMD

General Information

Summary To evaluate the safety and tolerability of human somatic cell nuclear transfer embryonic stem cell derived retinal pigmented epithelial(SCNT-hES-RPE) cellular therapy in patients with advanced dry AMD.
Description To evaluate the safety and tolerability of the SCNT-hES-RPEs, to assess the number of SCNT-hES-RPE cells to be transplanted in future studies and to evaluate on an exploratory basis potential efficacy endpoints to be used in future studies of SCNT-hES-RPE cellular therapy.
Clinical trials phase Phase 1
Start date (estimated) 2015-05-01
End date (estimated) 2019-04-30
Clinical feature
Label atrophic macular degeneration
Link http://www.ebi.ac.uk/efo/EFO_1001492
Description Dry AMD is most common type of macular degeneration and affects 90% of the people who have the condition. In the dry form, there is a breakdown or thinning of the layer of retinal pigment epithelial cells (RPE) in the macula. No medical or surgical treatment is available for this condition.

Administrative Information

NCT number NCT03305029
ICTRP weblink http://apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT03305029
Other study identifiers
Name CHA2015-08-141
Source weblink https://clinicaltrials.gov/ct2/show/NCT03305029
Regulatory body approval
Country
Public contact
Email songwkmd@daum.net
Country
Sponsors CHA University

Cell Line

Recruitment

Recruitment Status Enrolling by invitation
Estimated number of participants 3
Contact institutions/departments